ArticleReproductive health2026
Association of serum uric acid during pre-pregnancy with adverse pregnancy outcomes among women conceived by in-vitro fertilization: a retrospective cohort study.
Article in Reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMaternal serum uric acid (UA) levels have been linked to adverse pregnancy outcomes, but no studies have yet examined this association in women undergoing assisted reproductive technology. This study aimed to investigate the relationship between pre-pregnancy UA levels and adverse pregnancy outcomes in women conceived via in vitro fertilization and embryo transfer (IVF-ET).
methodsThis retrospective cohort study included 2 111 singleton pregnancies conceived via IVF-ET, delivered at Peking University Third Hospital between 1 January 2017 and 30 April 2022. Restricted cubic splines were used to test nonlinear relationships between serum UA during pre-pregnancy and adverse outcomes, and multivariable logistic regression to calculate odds ratio (OR) and 95% confidence interval (CI).
resultsOf the 2 111 women, no significant associations were found between pre-pregnancy UA levels and preeclampsia, preterm birth, or macrosomia. However, a J-shaped relationship was observed for gestational diabetes mellitus (GDM) and low birth weight (LBW), and an inverse U-shaped relationship for gestational hypertension (GH). Reflecting these distinct non-linear topologies, statistically significant peak risks were observed and reported at different strata: women in the higher quintile (4th quintile) of UA had a 3.20-fold increased risk of GH (adjusted OR 3.20, 95% CI 1.23, 8.33) and a 1.38-fold increased risk of GDM (adjusted OR 1.38, 95% CI 1.01, 1.88) compared with the lowest quintile. Conversely, the risk of LBW accelerated sharply and peaked at the highest quintile (5th quintile) (adjusted OR 1.98, 95% CI 1.11, 3.54). In the subgroup analysis, the positive association between pre-pregnancy UA and LBW was more pronounced among patients with day 5 embryo transfer.
conclusionsThese findings suggest that optimizing serum UA levels in women planning pregnancy, particularly those undergoing IVF-ET, may have important clinical implications for improving pregnancy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.